Proposal to Change Brand of Oral Flecainide Acetate

Page 1

CONSULTATION

Proposal to change the funded brand of oral flecainide acetate 29 January 2019

What we’re proposing We propose the following changes to the funded brands of oral flecainide used in the prevention of supraventricular and ventricular arrhythmias:  the funded brand of flecainide acetate tab 50 mg would change from Tambocor (supplied by Radiant Health) to Flecainide BNM (supplied by Boucher) following a transition period starting on 1 September 2019; and 

the funded brand of flecainide acetate cap long-acting 100 mg and 200 mg would change from Tambocor CR (supplied by Radiant Health) to Flecainide Controlled Release Teva (supplied by Teva) following a transition period starting on 1 July 2019;

from the end of the transition periods, Flecainide BNM and Flecainide Controlled Release Teva would be the only funded brands in both the community and hospital settings.

No changes are proposed for the listing of flecainide inj 10 mg per ml, 15 ml ampoule (Tambocor). PHARMAC is aware of the importance of flecainide injections and would continue to ensure funding to this product is maintained. Flecainide is used in patients with certain cardiac arrythmias so in addition to general feedback to the proposal, we would like your specific feedback to help us develop any implementation support that may be required. 1. What would help health professionals support patients with a change in brand of medicine? 2. Are there any other types of implementation support that would be useful for patients or health professionals? Consultation closes at 4 pm on Monday 18 February 2019 and can be emailed to procurement@pharmac.govt.nz.

What would the effect be? For patients From 1 September 2019, people would have funded access to a new brand of oral flecainide acetate tab 50 mg (Flecainide BNM). From 1 July 2019, people would have funded access to a new brand of oral flecainide acetate cap longacting 100 mg and 200 mg (Flecainide Controlled Release Teva). During a three-month transition period, from 1 September 2019 to 30 November 2019 (cap long-acting 100 mg and 200 mg) and from 1 November 2019 till 31 January 2020 (tab 50 mg), the subsidy would be reduced for the other currently A1230474

PHARMAC CONSULTATION

1


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.